Ping An Good Doctor, Zhongxin partner on CVD management platform

Chinese digital health platform Ping An Good Doctor (HK.1833) continues on a spree of deal-making, today announcing a partnership with Tianjin Zhongxin Pharmaceutical Group Corp., Ltd, (SH.600329) primarily focused on establishing an online cardiovascular disease (CVD) management platform in China. The partnership will extend into the full range of “internet+ medicine” services, including chronic disease management, artificial intelligence (AI)-assisted family doctor services, e-retail of pharma products, marketing, and insurance products.

Ping An Good Doctor is able to provide data from 300 million online consultations to guide chronic disease management. In terms of the CVD-focused platform, the aim will be to link with real-world hospitals and academic resources to provide scientific knowledge of cardiovascular disease, instruction in drug use, online and offline referral, post-operative rehabilitation, psychological intervention and other services.

Ping An Good Doctor has a team of over 5,000 in-house or externally partnered medical staff to support online consultations, and partners with over 3,100 major hospitals in China as well as a network of smaller institutions and pharmacies. Today’s deal is the third major “internet+ medicine” partnership struck with a pharma firm in recent weeks, following tie-ups with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd, Jointown Pharmaceutical Group Co., Ltd (600998.SH) previously reported by GBI.

Related news
China-based China Resources Sanjiu Medical & Pharmaceutical Co., Ltd (000999.SZ) and China Resources Pharmaceutical Investment Co., Ltd are set to shed respective their 100% holding in Sanjiu Hospital (GBI translation) for a consideration of RMB 719.35 million, according to an announcement from CR Sanjiu.
China-based health service platform Ping An Good Doctor (HK.1833) and compatriot pharma company China Resources Sanjiu Medical & Pharmaceutical Co., Ltd, have formed a strategic partnership focused on developing an “internet + medical” business model.
China-based Yisheng Biopharma Holdings Ltd picked up a clinical trial nod for its novel PIKA adjuvant-based therapeutic vaccine for rabies from the China National Medical Products Administration (NMPA).
  • 1538970153211
  • China
  • Drug
Felipe Bornier (PROS), a member of Brazil’s House of Representatives, proposed draft law 10377/18 to provide all spinal muscular atrophy (SMA) patients with free treatment through the Unified Health System (SUS).
One month after the Industrial Chamber of Argentine Pharmaceutical Laboratories (CILFA) and the Argentine Pharmaceutical Business Chamber (COOPERALA) rescinded a drug supply contract with the Comprehensive Medical Attention Program (PAMI), as GBI reported, PAMI has decided to bypass them as intermediates and purchase medicines straight from laboratories, starting November 1.
Recent news
by JULETT PINEDA SLEINAN | @JULEPINEDA Los precios acordados de 56 principios activos ya entraron en vigencia.
Brazil's National Agency of Health Surveillance (ANVISA) has approved the combined use of Bristol-Myers Squibb's programmed death-1 (PD-1) inhibitor Opdivo (nivolumab) with the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)-targeted Yervoy (ipilimumab) as a first-line therapy for untreated patients with intermediate- and poor-risk advanced or metastatic kidney cancer.
Quarta, 17 Outubro 2018 16:47 Escrito ou enviado por Catarina Marrao Uso de Opdivo (nivolumabe) associado a Yervoy (ipilimumabe) é o primeiro e o único tratamento a proporcionar aumento significativo de sobrevida global a pacientes com câncer renal metastático A biofarmacêutica global Bristol-Myers Squibb acaba de obter a aprovação da Agência Nacional de Vigilância Sanitária (ANVISA) para o uso combinado de seus imuno-oncológicos, Opdivo (nivolumabe) e Yervoy (ipilimumabe), como primeira linha de tratamento para pacientes com câncer renal avançado ou metastático de risco intermediário ou alto, não tratados previamente. Esta aprovação representa uma chance a mais para os pacientes que enfrentam a doença no brasil, tornando-se a única combinação aprovada de imunoterápicos para esta indicação em primeira linha de tratamento.
Brazil's National Health Surveillance Agency (ANVISA) approved a new therapeutic indication for Amgen's osteoporosis drug Xgeva (denosumab) to prevent skeletal problems in multiple myeloma (MM) patients.
São Paulo, 16 de outubro de 2018 - A Agência Nacional de Vigilância Sanitária (ANVISA) acaba de aprovar mais uma indicação para o Xgeva® (denosumabe), da biofarmaceutica Amgen.
Por Economidia 17 out 2018, 11h50 Entre os dias 09 e 11 de outubro de 2018, em Madri, Espanha, aconteceu a CPhI Worldwide, maior feira de negócios da indústria farmacêutica no mundo.
Brazil's National Health Surveillance Agency (ANVISA) has green lit Sanofi Pasteur's influenza vaccine Fluzone Sênior designed for people aged 65 and older, concluding an evaluation that started last year, as GBI reported.
Analytics Snapshot

Actionable intelligence at your fingertips.